Description: Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Home Page: www.prothena.com
PRTA Technical Analysis
77 Sir John Rogerson’s Quay
Dublin,
2
Ireland
Phone:
353 1 236 2500
Officers
Name | Title |
---|---|
Dr. Gene G. Kinney Ph.D. | Pres, CEO & Director |
Mr. Tran B. Nguyen M.B.A. | CFO & Chief Strategy Officer |
Mr. Brandon S. Smith | Chief Operating Officer |
Ms. Carol D. Karp | Chief Regulatory Officer |
Dr. Hideki Garren M.D., Ph.D. | Chief Medical Officer |
Ms. Karin L. Walker CPA, CPA | Chief Accounting Officer & Controller |
Dr. Wagner M. Zago | Chief Scientific Officer |
Ms. Jennifer Zibuda | Director of Investor Relations & Communication |
Mr. Michael J. Malecek | Chief Legal Officer |
Ms. Yvonne M. Tchrakian | Company Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 64.1026 |
---|---|
Trailing PE: | 36.2517 |
Price-to-Book MRQ: | 6.9771 |
Price-to-Sales TTM: | 549.2818 |
IPO Date: | 2012-12-21 |
Fiscal Year End: | December |
Full Time Employees: | 82 |